Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Amir London, CEO of Israel's Kamada — a major biopharmaceutical company that already has an FDA-approved therapy for alpha-1 antitrypsin deficiency, and is now pursuing an inhaled AAT drug for the same disease.
All content for Rare Care Podcast is the property of Rare Care Podcast and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Amir London, CEO of Israel's Kamada — a major biopharmaceutical company that already has an FDA-approved therapy for alpha-1 antitrypsin deficiency, and is now pursuing an inhaled AAT drug for the same disease.
196: An Interview With Lisa Shea, Director of Global Patient Advocacy and Engagement for Immunology at Johnson & Johnson
Rare Care Podcast
7 minutes
2 weeks ago
196: An Interview With Lisa Shea, Director of Global Patient Advocacy and Engagement for Immunology at Johnson & Johnson
Rare Care Podcast
Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Amir London, CEO of Israel's Kamada — a major biopharmaceutical company that already has an FDA-approved therapy for alpha-1 antitrypsin deficiency, and is now pursuing an inhaled AAT drug for the same disease.
